surpass cvot tirzepatide results SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I Effects of tirzepatide on adjudicated
Pay in 4 interest-free payments of $7.45 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1


00032-X/asset/f312f4e3-50d1-472f-90c9-896e4cef8e23/main.assets/gr1_lrg.jpg)

























